Trial Profile

Clinical trial of SPL84-23 for muco-obstructive diseases and idiopathic pulmonary fibrosis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPL 84 (Primary)
Indications Idiopathic pulmonary fibrosis; Obstructive airway disorders
Focus Adverse reactions
Sponsors SpliSense

Most Recent Events

11 Sep 2023 New trial record
06 Sep 2023 According to a SpliSense media release, results from a phase 1/2 clinical trial in CF supports for further development of SPL84 for treatments for muco-obstructive diseases and idiopathic pulmonary fibrosis which are expected to enter the clinic next year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com